about
The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic CephalalgiasClinical aspects of headache in HIV.Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies.Migraine preventive therapy: selection of appropriate patients and general principles of management.The pharmacological management of migraine, part 1: overview and abortive therapy.Dihydroergotamine: role in the treatment of migraine.Adverse effects of medications commonly used in the treatment of migraine.Current and emerging treatment options for migraine and other primary headache disorders.Paradoxical and bidirectional drug effects.MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine.Orally inhaled dihydroergotamine: a review.Headache, cerebral aneurysms, and the use of triptans and ergot derivatives.Is the Generally Held View That Intravenous Dihydroergotamine Is Effective in Migraine Based on Wrong "General Consensus" of One Trial? A Critical Review of the Trial and Subsequent Quotations.Combination ergotamine and caffeine improves seated blood pressure and presyncopal symptoms in autonomic failure.Application of a strategy based on metabolomics guided promoting blood circulation bioactivity compounds screening of vinegar.Migraine management in community pharmacies: practice patterns and knowledge of pharmacy personnel in Thailand.Familial and sporadic hemiplegic migraine: diagnosis and treatment.Continuous Flow Homolytic Aromatic Substitution with Electrophilic Radicals: A Fast and Scalable Protocol for Trifluoromethylation.
P2860
Q26786375-C72A6185-90D4-442A-BE20-EA276C34EADDQ30805163-22C42E66-60BE-40A1-814C-62EF1B31B116Q35270090-4EEF70FB-4AA2-47AE-8C0E-BA7C1E2F0515Q36558665-49890CF4-A224-4F11-A947-37C9C2FCC576Q37340160-E1E57F3F-5FB9-4C32-8143-FCC1EE08EDD3Q37558538-B762B9AD-E2DA-499C-B597-96FECC3B3CA1Q37600874-471F8DFD-2775-4AC0-BE29-5B3C5626C51EQ37610198-971CF3A1-4B20-4CF5-81AF-E6E09F80D45BQ37978338-EFF812D3-E847-474D-9BC8-673FA2316787Q38031885-4469FC0E-2958-42FE-9562-31535F1FE993Q38136257-6C031390-ADD2-48D4-87B1-8BFEDE0E43B1Q38436592-A0979F11-524D-4F47-A21E-212775F87C46Q38946597-2C8E5134-28C3-48FC-87E3-C35B6ECD2462Q41893414-2B30F724-F825-491F-9024-85DBB82E628AQ43084227-6B58158F-1CA1-404D-BEDC-F31BDEE69B03Q45892542-5399CF7F-3F93-4AE1-A90D-309467082E35Q46069840-7CA16C8D-942B-43FA-A6AD-3A294F5910D2Q48280782-96A56E15-C98C-4D0A-B7F2-1EB44EBB216A
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Ergotamine and dihydroergotamine: a review.
@ast
Ergotamine and dihydroergotamine: a review.
@en
Ergotamine and dihydroergotamine: a review.
@nl
type
label
Ergotamine and dihydroergotamine: a review.
@ast
Ergotamine and dihydroergotamine: a review.
@en
Ergotamine and dihydroergotamine: a review.
@nl
prefLabel
Ergotamine and dihydroergotamine: a review.
@ast
Ergotamine and dihydroergotamine: a review.
@en
Ergotamine and dihydroergotamine: a review.
@nl
P2860
P1476
Ergotamine and dihydroergotamine: a review.
@en
P2860
P2888
P356
10.1007/S11916-003-0011-7
P407
P577
2003-02-01T00:00:00Z
P6179
1048986473